Normunity is a biotech company founded in 2021 with a mission to develop innovative precision immuno-oncology medicines. The company, headquartered in Boston, Mass. and West Haven, Conn., is focused on creating a new class of medicines called immune normalizers, which aim to unlock the body's natural immune response against cancer. Leveraging an ongoing collaboration with Dr. Lieping Chen at Yale School of Medicine, Normunity is targeting novel mechanisms of immune disruption in cancer through proprietary discovery platforms.
Normunity's approach involves addressing barriers to normal immune function in cancer, with a particular focus on mechanisms that drive the exclusion of T-cells from immune-sensitive tumors. The company recently secured a $65.00M Series A investment from notable investors including Canaan Partners, Osage University Partners, Sanofi Ventures, and Taiho Ventures on 25 October 2022.
With a strong focus on biotechnology, Normunity is poised to make significant strides in the field of immuno-oncology and has attracted substantial support from key players in the venture capital space. As the company advances its pipeline of immune normalizers, it presents a compelling opportunity for investors looking to participate in the future of cancer treatment innovation.
